Aldeyra secures FDA SPA for ADX-2191 lymphoma trial – key milestone

Aldeyra Therapeutics (NASDAQ:ALDX) filed a Form 8-K reporting receipt of a Special Protocol Assessment (SPA) agreement letter from the FDA covering the pivotal trial design for ADX-2191, its investigational treatment for primary vitreoretinal lymphoma (PVRL).

Rhea-AI Filing Summary

Aldeyra Therapeutics (NASDAQ:ALDX) filed a Form 8-K reporting receipt of a Special Protocol Assessment (SPA) agreement letter from the FDA covering the pivotal trial design for ADX-2191, its investigational treatment for primary vitreoretinal lymphoma (PVRL). The SPA signals FDA concurrence that the study’s endpoints and analysis, if achieved, are sufficient for a future New Drug Application, materially reducing regulatory risk and potentially accelerating review. The related press release is furnished as Exhibit 99.1 under Item 7.01, with the same event noted under Item 8.01. No financial data, guidance, or operational changes were disclosed.

Positive

• FDA Special Protocol Assessment secured for ADX-2191 pivotal PVRL trial, materially lowering regulatory risk

Negative

• None.

Insights

Regulatory Affairs Analyst

TL;DR: FDA SPA sharply lowers regulatory risk—clear positive.

The SPA confirms FDA alignment on ADX-2191’s pivotal study design, endpoints and statistics—crucial for an orphan indication where trial size is constrained. Meeting those agreed endpoints should satisfy efficacy requirements for an NDA, thus increasing the probability of approval and shortening time to market. The milestone enhances the asset’s value for potential partnerships and improves financing leverage with minimal dilution. With no safety concerns flagged, the disclosure is an unambiguous catalyst for ALDX.

Risk Analyst

TL;DR: SPA helps, but funding and execution risks remain.

Protocol risk is gone, yet efficacy still must be demonstrated in a rare, heterogeneous patient pool, and commercial upside is capped by market size. The 8-K omits cash-runway or trial-start details, leaving dilution risk unresolved. An SPA is not approval; any protocol deviation can void the agreement. Until clinical data read out, overall impact is neutral.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What regulatory milestone did [[ALDX]] announce on June 26 2025?

The company received a Special Protocol Assessment agreement letter from the FDA for ADX-2191.

Which condition is ADX-2191 intended to treat according to the 8-K?

ADX-2191 targets primary vitreoretinal lymphoma (PVRL).

How does an FDA SPA affect [[ALDX]]’s pivotal trial?

It confirms FDA agreement on design and endpoints, meaning success should support an NDA and reduces regulatory uncertainty.

Did Aldeyra provide financial guidance in this filing?

No. The 8-K only furnished the press release without financial statements or guidance.

Where can investors read the full press release related to the SPA?

It is filed as Exhibit 99.1 to the Form 8-K dated June 26 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 07:01 AM Learn about SEC filing dates

false 0001341235 0001341235 2025-06-26 2025-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2025

ALDEYRA THERAPEUTICS, INC.

(Exact name of Registrant as specified in its charter)

Delaware		001-36332		20-1968197
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

131 Hartwell Avenue, Suite 320

Lexington, MA 02421

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (781) 761-4904

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange  on which registered
Common Stock, $0.001 par value per share		ALDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On June 26, 2025, Aldeyra Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) to announce the receipt of a Special Protocol Assessment Agreement Letter (the “SPA”) from the U.S. Food and Drug Administration (the “FDA”) for ADX-2191, an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (“PVRL”). The Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

This information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 8.01. Other Events.

As reported under Item 7.01 of this Current Report on Form 8-K, on June 26, 2025, the Company announced the receipt of the SPA from the FDA for ADX-2191 for the treatment of PVRL.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Aldeyra Therapeutics, Inc. Press Release dated June 26, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALDEYRA THERAPEUTICS, INC.
	By:	/s/ Todd C. Brady
		Name:	Todd C. Brady M.D., Ph.D.
		Title:	Chief Executive Officer
Dated June 26, 2025

2